

Now Available – A New Treatment for Alzheimer's Disease

The NeuroAD™ System


- The Only Proven Non-Pharmaceutical Treatment for Patients with Alzheimer's Disease (AD)
- CE Approved System for Treatment of Mild-to-Moderate AD
- Patented Technology Combines **Cognitive Training & Transcranial Magnetic Stimulation (rTMS)**
- Strong Results across 8 Clinical Trials with Performance Several Times Greater than Rx & Non-Rx Options

Highly Targeted Therapy to Improve Cognitive Function and Alter Disease Progression

COGNITIVE THERAPY +
TRANSCRANIAL MAGNETIC STIMULATION)



SIGNIFICANT
COGNITIVE IMPROVEMENT



CONCURRENT – TARGETED AT SAME BRAIN REGIONS)

FAR GREATER IMPACT THAN Rx)

Advance Your Care of Patients with Alzheimer's Disease

- Clinically significant ADAS-cog improvement
- More impactful cognitive improvement than Rx
- Non-invasive and adjunctive to medications
- No reported side effects

Technology & Treatment

The Technology

Concurrent TMS with Cognitive Training

- Focused Transcranial Magnetic Stimulation (TMS)
- Customized Cognitive Training exercises, aligned to patient's specific abilities
- Exercised Brain Regions receive simultaneous TMS Therapy
- Clinical Impact: Combined Therapy Improves Brain Plasticity and Cognitive Function

Treatment

- Pre-treatment: MRI to locate & mark brain regions
- Concentrated Clinical Treatment:
 - 1 Hour Session, 5 days week, 6 weeks
 - 3 Brain Regions targeted each day

“It makes the brain circuits work better, and this leads to a striking improvement in cognitive abilities”

Dr. Pascual-Leone, Harvard Medical



III. Clinical Trial Results with NeuroAD™ Treatment

Significant Improvement of Patients

Clinical Results

Clinical Trials	# of Patients	Treatment Arm	Placebo Arm	Difference between Arms	Statistical Significance (p)
Israel-1	8	-3.9		-3.9	0.01
Israel-2	15	-3.8	0.5	-4.2	0.04
Harvard-1	21	-5.4 (10 pts)	0.7 (6 pts) -2.0 (5 pts)	-6.1 -3.4	<0.01
Israel-3	16	-1.5	2.1	-3.5	
Korea-1	19	-4.3	-1.7	-2.8	0.02
Korea-2	26	-5.4	-2.9	-2.5	
Patient Avg.	105	-3.9	0.10	-4.0	


Note: Clinical Results do not include the FDA and other Worldwide Clinical Trials currently underway.

Over 100 patients studied across multiple clinical trials showed significant improvement in treatment over placebo & published drug results


Superior Clinical Outcomes

Dramatic improvement vs. Rx treatment

Neuronix Therapy Clinical Results



Increased Brain Activity following NeuroAD



Harvard Medical Study

- High efficacy demonstrated
- Slow decline over time
- Safe Procedure; limited side-effects
- Adjunctive to existing medications

Neuronix Therapy has been clinically proven to reverse the course of AD far beyond present Pharmaceuticals and Non-Treatment Pathways

CE Approval

Cleared for Clinical Use Throughout Europe in Mild-to-Moderate Alzheimer's Patients



Non-Invasive Cortical Enhancer System Transcranial Magnetic Stimulation for the Treatment of Alzheimer's Disease

Neuronix Clinical Partners

- Beth Israel Deaconess Medical Center



Beth Israel Deaconess
Medical Center

- Asaf Harofe Hospital



- Harvard Medical School



HARVARD
MEDICAL SCHOOL

- NYU Langone Medical Center



- Cleveland Clinic



Cleveland Clinic

- Banner Sun Health Research Institute

